Pdt Partners, LLC Aprea Therapeutics, Inc. Transaction History

Pdt Partners, LLC

  • $1.01 Billion
  • Q1 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.62 - $1.94 $18,257 - $57,127
-29,447 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$1.59 - $3.16 $179,913 - $357,563
-113,153 Reduced 79.35%
29,447 $55,000
Q4 2021

Feb 14, 2022
BUY
$2.87 - $5.58 $157,465 - $306,152
54,866 Added 62.54%
142,600 $409,000
Q3 2021

Nov 15, 2021
SELL
$3.43 - $5.63 $125,195 - $205,495
-36,500 Reduced 29.38%
87,734 $448,000
Q2 2021

Aug 16, 2021
BUY
$4.05 - $5.5 $503,147 - $683,287
124,234 New
124,234 $606,000

Others Institutions Holding APRE

# of Institutions
3
Shares Held
999
Call Options Held
0
Put Options Held
0
View Full List

About Aprea Therapeutics, Inc.

APRE Quotes by TradingView
  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email